Phase 1 healthy volunteer trial ongoing, with data expected in 2Q25Kymera plans to initiate a KT-621 Phase 1b trial in atopic ...

Kymera Therapeutics (KYMR) announced its corporate goals for 2025, including anticipated progress on its clinical pipeline of immunology ...

Biogen expects revenue from new launches to exceed its current sales by 2028 and does not feel the need to chase additional ...

Studies conducted in mice have shown that the COVID-19 vaccine being developed by researchers at the University of São Paulo's Medical School (FM-USP) in Brazil is safe and efficacious.

The global clinical informatics market, valued at US$ 198.33 Billion in 2023, is forecasted to grow at a robust CAGR of 16.0% ...

Pilot runs in Europe and South America show breakthrough efficiency in monoclonal antibody production with unprecedented cost ...